User:FletaAlderman
Revision as of 07:03, 2 May 2019 by FletaAlderman (talk | contribs)
Nonetheless, all of this potential does not come cheaply. Hospira's 2012 Annual Report estimates a cost of $100 $200M per approved biosimilar drug over a 7 8 year period of research and development.
